IIN - IntriCon Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
13.46
+0.26 (+1.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close13.20
Open13.39
Bid0.00 x 800
Ask0.00 x 800
Day's Range12.74 - 13.66
52 Week Range9.84 - 28.31
Volume29,905
Avg. Volume69,384
Market Cap119.781M
Beta (5Y Monthly)1.02
PE Ratio (TTM)N/A
EPS (TTM)-0.74
Earnings DateMay 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateSep 12, 2001
1y Target Est26.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-30% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    IntriCon Reports First Quarter 2020 Results

    ARDEN HILLS, Minn., May 19, 2020 -- IntriCon Corporation (NASDAQ: IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical.

  • GlobeNewswire

    IntriCon Acquires Emerald Medical Services

    Synergistic joint development and manufacturing capability expands market opportunity in surgical navigationProvides immediate access to technology platform serving new high.

  • ACCESSWIRE

    Intricon Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 19, 2020 / Intricon Corp. (NASDAQ:IIN) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 19, 2020 at 5:00 PM Eastern ...

  • GlobeNewswire

    IntriCon to Announce 2020 First-Quarter Results on Tuesday, May 19, 2020

    ARDEN HILLS, Minn., May 11, 2020 -- IntriCon Corporation (NASDAQ: IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical.

  • GlobeNewswire

    IntriCon Announces Appointment of Sara Hill as Chief Human Resource Officer

    IntriCon Corporation (IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical devices, today announced Sara Hill has been appointed Chief Human Resource Officer. As a key member of IntriCon's executive leadership team, Ms. Hill will lead the company’s global human resources function, overseeing the efforts of organizational and leadership development, talent acquisition and talent management, succession planning and total rewards.

  • GlobeNewswire

    INTRICON OFFERS COVID-19 RELATED BUSINESS UPDATE

    IntriCon Corporation (IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical devices, today provided an update on the actions it is taking in response to the COVID-19 pandemic and preliminary first quarter 2020 financial results. IntriCon has implemented several measures in recent weeks in an effort to address and prioritize the health and safety of its employees and their communities, while at the same time continuing to support customers and partners. Health and Safety: Based on the expertise and recommendations from federal and local government and health agencies, IntriCon has implemented remote and flexible work arrangements for employees wherever possible.

  • GlobeNewswire

    IntriCon Corporation Announces Change to Virtual Meeting Format for its Annual Meeting of Shareholders to be Held on April 28, 2020

    IntriCon Corporation (IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical devices, today announced a change in the location of its Annual Meeting of Shareholders to be held on Tuesday, April 28, 2020 at 9:00 a.m., Central Time. Due to the emerging public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of its shareholders, employees and other meeting participants, the location of the Annual Meeting has been changed and will be held in a virtual meeting format only. To be admitted to the Annual Meeting at www.virtualshareholdermeeting.com/IIN2020, shareholders must enter the control number found on their previously received proxy card, voting instruction form or notice.

  • GlobeNewswire

    IntriCon Appoints Heather Rider to its Board of Directors

    IntriCon Corporation (IIN), a designer, developer and manufacturer of miniature interventional, implantable and body-worn medical devices, today announced the appointment of Heather Rider to the company’s Board of Directors, effective March 20, 2020. “I am delighted to welcome Heather to our board of directors,” said Mark Gorder, president and chief executive officer of IntriCon.

  • Did You Miss IntriCon's (NASDAQ:IIN) 82% Share Price Gain?
    Simply Wall St.

    Did You Miss IntriCon's (NASDAQ:IIN) 82% Share Price Gain?

    While IntriCon Corporation (NASDAQ:IIN) shareholders are probably generally happy, the stock hasn't had particularly...

  • Thomson Reuters StreetEvents

    Edited Transcript of IIN earnings conference call or presentation 24-Feb-20 10:00pm GMT

    Q4 2019 IntriCon Corp Earnings Call

  • GlobeNewswire

    IntriCon Reports Fourth Quarter and Full Year 2019 Results

    ARDEN HILLS, Minn., Feb. 24, 2020 -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices,.

  • GlobeNewswire

    IntriCon to Announce 2019 Fourth Quarter and Full Year Results on Monday, February 24, 2020

    ARDEN HILLS, Minn., Feb. 13, 2020 -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn devices, today announced that it will.

  • What Did IntriCon Corporation's (NASDAQ:IIN) CEO Take Home Last Year?
    Simply Wall St.

    What Did IntriCon Corporation's (NASDAQ:IIN) CEO Take Home Last Year?

    Mark Gorder has been the CEO of IntriCon Corporation (NASDAQ:IIN) since 2001. First, this article will compare CEO...

  • Is IntriCon Corporation (IIN) A Good Stock To Buy?
    Insider Monkey

    Is IntriCon Corporation (IIN) A Good Stock To Buy?

    "Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]

  • GlobeNewswire

    IntriCon Awarded 2019 Medtronic Supplier Excellence Award

    ARDEN HILLS, Minn., Dec. 02, 2019 -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices,.

  • Thomson Reuters StreetEvents

    Edited Transcript of IIN earnings conference call or presentation 4-Nov-19 10:00pm GMT

    Q3 2019 IntriCon Corp Earnings Call

  • Calculating The Fair Value Of IntriCon Corporation (NASDAQ:IIN)
    Simply Wall St.

    Calculating The Fair Value Of IntriCon Corporation (NASDAQ:IIN)

    Today we'll do a simple run through of a valuation method used to estimate the attractiveness of IntriCon Corporation...

  • Mario Gabelli Continues to Buy AbbVie, Axalta
    GuruFocus.com

    Mario Gabelli Continues to Buy AbbVie, Axalta

    9 High Conviction Stocks for GAMCO Investors Continue reading...

  • GlobeNewswire

    IntriCon to Present at the 2019 Stifel Healthcare Conference

    ARDEN HILLS, Minn., Nov. 05, 2019 -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn devices, today announced that Mark.

  • 3 ‘Strong Buy’ Stocks Investment Firm B. Riley FBR Recommends
    TipRanks

    3 ‘Strong Buy’ Stocks Investment Firm B. Riley FBR Recommends

    To everything turn, turn, turn.There is a season earn, earn, earn.So the song almost goes. With earnings season in full swing, eagle eyed market watchers are looking for opportunities amongst the deluge of reports. With this in mind, we decided to take a look at three stocks investment firm B. Riley FBR thinks are about to provide investors with some solid upside. Importantly, according to TipRanks \-- a Financial Accountability Engine that measures and ranks analysts based on their performance -- all 3 are currently Strong Buys.Let's dive in:Celsius Holdings (CELH)Energy drink maker Celsius Holdings will release third-quarter results Thursday, and analysts’ consensus estimates anticipate Q3 revenue of $18.3 million, while staying on target of $100 million revenue for the full year. Following on from a record 2Q revenues of $16.1 million, over 70% more than the same quarter last year, and an increase of gross profit by 70%, expectations are high.Celsius’s end game is to become a leading global brand, and as part of its expansion strategy, it recently acquired Nordic wellness company, Func Food. Apart from offering a new distribution platform for Europe, the acquisition is valued way below revenue multiple and will provide immediate accretion to shareholders. This follows the August launch of BCAA, a new post workout product line, further continuing Celsius’s expansion.B.Riley FBR’s analyst Jeff Van Sinderen thinks demand for the company's product is growing, noting, “We continue to believe that, with enthusiastic consumer adoption and products that remain differentiated in the marketplace, CELH is positioned to continue to capture market share from legacy energy drinks… With more resources going into the North American segment and opportunity for incremental revenue through category expansion, strong opportunity to grow the EU business that is now under the company’s direct control and the company on track to post rapid growth in FY19 with potential to accelerate in FY20.”The analyst suggests that if everything goes as planned, buy-rated CELH will be a $10 stock in the next 12 months, implying well over 170% return. (To watch Sinderen's track record, click here)Over the last three months, CELH stock has received 3 "buy" ratings, with no "hold" or "sell" ratings. As a result, the stock has a ‘Strong Buy’ analyst consensus rating. These analysts believe (on average) that the stock has big upside potential of over 170% from the current share price. This would take CELH from $3.56 all the way to $9.67. (See Celsius stock analysis on TipRanks)Quantum (QMCO) Video storage specialist, Quantum, reports its fiscal second-quarter earnings today after market closes. Quantum provides high streaming performance for video and rich media applications, alongside large-scale low-cost data protection.The company’s product line has been continually expanding, and now includes StorNext, its award-winning file system, F-Series, a new line of NVMe storage arrays, and its removable storage systems R-Series, amongst others. It also recently announced its new line of storage-as-a-service offering, Quantum Distributed Cloud Services.The enterprise storage sector is crowded, including big name players such as DELL, IBM, and ORCL vying for market share, but B.Riley FBR’s 5-star analyst Craig Ellis thinks Quantum has strong long-term fundamental and stock upside potential. As a result, the analyst reiterated a Buy rating on QMCO stock along with a $7.25 price target, which implies about 17% upside from current levels.Ellis noted, “We preview an in-line F2Q20 with our and Street's at-midpoint estimates, and an outlook affirming our forecasts and headline consensus. As such, we believe the financial performance will indicate QMCO is tracking toward FY20’s sales, gross margin, and adjusted EBITDA targets [...] If our three-year forecasts play out, the relative growth and EPS expansion will likely sharply outpace peers, arguing for relative multiple expansion. While debt cost concerns persist, we believe the issue is manageable, with cash generation and strategic options. We expect an up-list from OTC in the near future and, with that, a boost to liquidity, further removing an overhang for stock performance."This is in line with other analysts’ view on QMCO’s prospects, as it gets a Strong Buy rating from the Street, with an average target price of $7.08, just slightly below Ellis’s target. (See Quantum stock analysis on TipRanks)Intricon (IIN)Riley FBR’s final recommendation is Intricon, a designer and manufacturer of miniature body-worn devices. The company’s emphasis revolves around three different markets: professional audio communications, hearing health and medical.Unlike the previous 2 recommendations, Intricon has just posted its 3Q19 earnings, with most results coming in slightly below estimates. Net revenue came in at $26.9 million, down from 3Q18 of $29.6 million, and gross margin came in at 25.2%, down from 31.6% in the prior-year third quarter.The underwhelming report hasn’t put off B. Riley FBR’s analyst Andrew D'Silva, who reiterated a Buy rating on the stock along with a $35 price target. This provides Intricon with upside of 90% from its current price of $18.37. (To watch D'Silva's track record, click here)D’silva believes there are several short-term catalysts which can propel Intricon forward. Among those are its largest customer, Medtronic, increasing international roll out of the MiniMed 670G Insulin Pump System, the unveiling of its next iteration, the MiniMed 780G, and the FDA providing recommendations around the OTC Hearing Aid Act.Final rules for the OTC Hearing Aid Act should be released in the next 6 months, with a draft expected later this month. D’silva says, “This is important because IIN's value-based hearing healthcare (VBHH) sales channels are expected to meaningfully benefit from the FDA finalizing its rules, as it is expected to provide the industry with clarity, which we believe should clear hurdles for IIN related to partnering opportunities with other DTC/VBHH providers.”Intricom’s cheerleaders are few but loud, with all 3 analysts polled over the last 3 months giving the stock the thumbs up. TipRanks analytics showcase IIN as a Strong Buy, while the average price target stands at $32.33 -- 76% upside from current levels. (See Intricon stock analysis on TipRanks)

  • GlobeNewswire

    Intricon Reports Third Quarter 2019 Results

    ARDEN HILLS, Minn., Nov. 04, 2019 -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices,.

  • GlobeNewswire

    IntriCon to Announce 2019 Third-Quarter Results on Monday, November 4, 2019

    ARDEN HILLS, Minn., Oct. 21, 2019 -- IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn devices, today announced that it will.

  • The IntriCon (NASDAQ:IIN) Share Price Has Gained 235%, So Why Not Pay It Some Attention?
    Simply Wall St.

    The IntriCon (NASDAQ:IIN) Share Price Has Gained 235%, So Why Not Pay It Some Attention?

    IntriCon Corporation (NASDAQ:IIN) shareholders might be concerned after seeing the share price drop 17% in the last...

  • GlobeNewswire

    IntriCon Announces Appointment of Craig Sandbulte as Vice President of Quality and Regulatory Affairs; Succeeds Greg Gruenhagen Upon Retirement

    IntriCon Corporation (IIN), a designer, developer, manufacturer and distributor of miniature and micro-miniature body-worn devices, today announced Craig Sandbulte has been appointed VP of Quality and Regulatory Affairs. “We are delighted to welcome Craig to the IntriCon team,” said Mark Gorder, President and Chief Executive Officer at IntriCon. Mr. Sandbulte brings more than 20 years of experience working in various quality roles within the medical device industry, most recently as Vice President of Global Quality Assurance at Cantel Medical.

  • Thomson Reuters StreetEvents

    Edited Transcript of IIN earnings conference call or presentation 6-Aug-19 9:00pm GMT

    Q2 2019 IntriCon Corp Earnings Call